Piramal Pharma Limited (PPLPHARMA)

Name: Piramal Pharma Limited (PPLPHARMA) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities.

Números-chave

Capitalização de mercado: ₹276 billion
Receita (exercício encerrado em 2026-03-31): ₹87.6B
Lucro líquido: (₹3.3B)
Margem bruta: 59.1%
Margem líquida: -3.7%

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Receita total	₹87.6B	₹90.6B	₹81.1B	₹70.3B	—
Lucro bruto	₹51.8B	₹54.9B	₹48.5B	₹40.3B	—
Resultado Operacional (EBIT)	₹1.5B	₹6.8B	₹4.6B	(₹480M)	—
Resultado líquido	(₹3.3B)	₹911M	₹178M	(₹1.9B)	—

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de PPLPHARMA. /companies/us/PPLPHARMA

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.